Eric M Lewandowski
Overview
Explore the profile of Eric M Lewandowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lewandowski E, Zhang X, Tan H, Jaskolka-Brown A, Kohaal N, Frazier A, et al.
Nat Commun
. 2025 Feb;
16(1):1266.
PMID: 39893201
SARS-CoV-2 main protease, M, is responsible for processing the viral polyproteins into individual proteins, including the protease itself. M is a key target of anti-COVID-19 therapeutics such as nirmatrelvir (the...
2.
Lewandowski E, Zhang X, Tan H, Jaskolka-Brown A, Kohaal N, Frazier A, et al.
bioRxiv
. 2024 Apr;
PMID: 38617221
SARS-CoV-2 main protease, M , is responsible for the processing of the viral polyproteins into individual proteins, including the protease itself. M is a key target of anti-COVID-19 therapeutics such...
3.
Ou J, Lewandowski E, Hu Y, Lipinski A, Aljasser A, Colon-Ascanio M, et al.
PLoS Pathog
. 2023 Aug;
19(8):e1011592.
PMID: 37651467
The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As Mpro inhibitor use...
4.
Hu Y, Lewandowski E, Tan H, Zhang X, Morgan R, Zhang X, et al.
ACS Cent Sci
. 2023 Aug;
9(8):1658-1669.
PMID: 37637734
The SARS-CoV-2 main protease (M) is the drug target of Pfizer's oral drug nirmatrelvir. The emergence of SARS-CoV-2 variants with mutations in M raised the alarm of potential drug resistance....
5.
Hu Y, Lewandowski E, Tan H, Zhang X, Morgan R, Zhang X, et al.
bioRxiv
. 2022 Sep;
PMID: 36119652
One Sentence Summary: Paxlovid resistant SARS-CoV-2 viruses with mutations in the main protease have been identified from clinical isolates.
6.
Ou J, Lewandowski E, Hu Y, Lipinski A, Morgan R, Jacobs L, et al.
Res Sq
. 2022 Sep;
PMID: 36052369
The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As Mpro inhibitor use...
7.
Ou J, Lewandowski E, Hu Y, Lipinski A, Morgan R, Jacobs L, et al.
bioRxiv
. 2022 Aug;
PMID: 35982672
The SARS-CoV-2 main protease (M ) is a major therapeutic target. The M inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As M inhibitor...
8.
Sacco M, Wang S, Adapa S, Zhang X, Lewandowski E, Gongora M, et al.
Nat Commun
. 2022 Jul;
13(1):4370.
PMID: 35902581
Treatment with β-lactam antibiotics, particularly cephalosporins, is a major risk factor for Clostridioides difficile infection. These broad-spectrum antibiotics irreversibly inhibit penicillin-binding proteins (PBPs), which are serine-based enzymes that assemble the...
9.
Lewandowski E, Kroeck K, Jacobs L, Fenske T, Witt R, Hintz A, et al.
Biochemistry
. 2022 Feb;
61(5):311-318.
PMID: 35156805
The human chemokines CCL19 and CCL21 bind to the G protein-coupled receptor (GPCR) CCR7 and play an important role in the trafficking of immune cells as well as cancer metastasis....
10.
Kuznik N, Solozobova V, Jung N, Grassle S, Lei Q, Lewandowski E, et al.
ACS Chem Biol
. 2021 Sep;
16(11):2103-2108.
PMID: 34506104
All current clinically approved androgen deprivation therapies for prostate cancer target the C-terminal ligand-binding domain of the androgen receptor (AR). However, the main transactivation function of the receptor is localized...